{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T04:06:07Z","timestamp":1749787567239,"version":"3.41.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n          <jats:sec>\n            <jats:title>Hintergrund<\/jats:title>\n            <jats:p>Untersuchung der morphologischen Ver\u00e4nderungen mittels optischer Koh\u00e4renztomographie-Angiographie (OCT-A) und der Entwicklung der Sehsch\u00e4rfe bei sekund\u00e4ren makul\u00e4ren Neovaskularisationen (sMNV) bei Chorioretinopathia centralis serosa (CCS) unter VEGF(\u201eanti-vascular endothelial growth factor\u201c)-Therapie.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patienten und Methoden<\/jats:title>\n            <jats:p>Retrospektive Untersuchung aller in Bezug auf eine Anti-VEGF-Therapie Treatment-naiven Augen, bei denen mittels Fluoreszeinangiographie (FA) und OCT\u2011A eine sMNV bei CCS nachgewiesen wurde und die zwischen Juli 2021 und Ende Dezember 2022 an der Universit\u00e4tsaugenklinik W\u00fcrzburg behandelt wurden. Alle Patienten wurden nach einem Pro-re-nata-Injektionsschema (PRN-Schema) behandelt und ein Jahr nachbeobachtet.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Ergebnisse<\/jats:title>\n            <jats:p>Es wurden 20\u00a0Augen von 16\u00a0Patienten mit sMNV bei CCS eingeschlossen. Durch FA konnte eine sMNV in 35\u202f% der F\u00e4lle und durch OCT\u2011A in 100\u202f% der F\u00e4lle gesichert werden. Morphologisch stellte sich die sMNV in der OCT\u2011A deutlich abgrenzbar bei 10\u00a0Augen als \u201esea-fan\u201c-artig und in 10\u00a0Augen als filamentf\u00f6rmig dar. Die Fl\u00e4chenabnahme der sMNV von 0,94\u202f\u00b1\u20091,2\u202fmm<jats:sup>2<\/jats:sup> bei der Baselineuntersuchung auf 0,72\u202f\u00b1\u20090,82\u202fmm<jats:sup>2<\/jats:sup> bei der Untersuchung nach 12\u00a0Monaten war statistisch nicht signifikant (<jats:italic>p<\/jats:italic>\u202f=\u20090,12). W\u00e4hrend des Beobachtungszeitraums wurden durchschnittlich 8,7\u202f\u00b1\u20091,6 intravitreale operative Medikamenteneingaben (IVOM) appliziert (5 bis 12 IVOM, Median\u00a09 IVOM).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diskussion<\/jats:title>\n            <jats:p>Sowohl FA als auch OCT\u2011A kamen zum Nachweis einer sMNV bei CCS zum Einsatz, wobei mittels OCT\u2011A ein zuverl\u00e4ssigerer Nachweis der sMNV gelang als mittels FA. Dabei konnten mit OCT\u2011A  zwei verschiedene sMNV-Typen nachgewiesen werden: 1) der \u201esea-fan\u201c-artige und\u00a02) der filamentf\u00f6rmige MNV-Typ. Die sMNV bei CCS ben\u00f6tigt innerhalb des ersten Behandlungsjahres eine vergleichbare Anzahl IVOM wie die Behandlung der neovaskul\u00e4ren altersabh\u00e4ngigen Makuladegeneration.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00347-025-02221-x","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T21:44:56Z","timestamp":1744148696000},"page":"442-452","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Morphologische und funktionelle Ver\u00e4nderungen der sekund\u00e4ren makul\u00e4ren Neovaskularisation bei Chorioretinopathia centralis serosa unter Anti-VEGF-Therapie","Morphological and functional changes of secondary macular neovascularization in central serous chorioretinopathy under anti-VEGF treatment"],"prefix":"10.1007","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9491-1846","authenticated-orcid":false,"given":"Nikolai","family":"Kleefeldt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Kuehnel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Reiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winfried","family":"Goebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jost","family":"Hillenkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antony","family":"William","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"issue":"12","key":"2221_CR1","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1007\/s00417-018-4144-0","volume":"256","author":"M Karacorlu","year":"2018","unstructured":"Karacorlu\u00a0M et\u00a0al (2018) Long-term follow-up of pachychoroid pigment epitheliopathy and lesion characteristics. Graefes Arch Clin Exp Ophthalmol 256(12):2319\u20132326","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2221_CR2","doi-asserted-by":"publisher","first-page":"100865","DOI":"10.1016\/j.preteyeres.2020.100865","volume":"79: p","author":"R Kaye","year":"2020","unstructured":"Kaye\u00a0R et\u00a0al (2020) Central serous chorioretinopathy: An update on risk factors, pathophysiology and imaging modalities. Prog Retin Eye Res 79: p:100865","journal-title":"Prog Retin Eye Res"},{"key":"2221_CR3","doi-asserted-by":"publisher","first-page":"100973","DOI":"10.1016\/j.preteyeres.2021.100973","volume":"86: p","author":"RF Spaide","year":"2022","unstructured":"Spaide\u00a0RF et\u00a0al (2022) Venous overload choroidopathy: A\u00a0hypothetical framework for central serous chorioretinopathy and allied disorders. Prog Retin Eye Res 86: p:100973","journal-title":"Prog Retin Eye Res"},{"issue":"8","key":"2221_CR4","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1097\/IAE.0b013e3182953df4","volume":"33","author":"DJ Warrow","year":"2013","unstructured":"Warrow\u00a0DJ, Hoang\u00a0QV, Freund\u00a0KB (2013) Pachychoroid pigment epitheliopathy. Retina 33(8):1659\u20131672","journal-title":"Retina"},{"key":"2221_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","volume":"48: p","author":"A Daruich","year":"2015","unstructured":"Daruich\u00a0A et\u00a0al (2015) Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48: p:82\u2013118","journal-title":"Prog Retin Eye Res"},{"issue":"11","key":"2221_CR6","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.oret.2020.07.026","volume":"4","author":"J Chhablani","year":"2020","unstructured":"Chhablani\u00a0J, Cohen\u00a0FB (2020) and G.\u00a0Central Serous Chorioretinopathy International, Multimodal Imaging-Based Central Serous Chorioretinopathy Classification. Ophthalmol Retin 4(11):1043\u20131046","journal-title":"Ophthalmol Retin"},{"issue":"2","key":"2221_CR7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/IAE.0000000000001138","volume":"37","author":"CK Cheng","year":"2017","unstructured":"Cheng\u00a0CK, Chang\u00a0CK, Peng\u00a0CH (2017) Comparison of Photodynamic Therapy Using Half-Dose of Verteporfin or Half-Fluence of Laser Light for the Treatment of Chronic Central Serous Chorioretinopathy. Retina 37(2):325\u2013333","journal-title":"Retina"},{"issue":"2","key":"2221_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ajo.2009.08.026","volume":"149","author":"M Reibaldi","year":"2010","unstructured":"Reibaldi\u00a0M et\u00a0al (2010) Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a\u00a0nonrandomized clinical trial. Am J Ophthalmol 149(2):307\u2013315","journal-title":"Am J Ophthalmol"},{"issue":"e0181479","key":"2221_CR9","first-page":"7","volume":"12","author":"F Haga","year":"2017","unstructured":"Haga\u00a0F et\u00a0al (2017) Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: A\u00a03-year follow-up study. PLoS ONE 12(e0181479):7","journal-title":"PLoS ONE"},{"issue":"10","key":"2221_CR10","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.ophtha.2018.04.021","volume":"125","author":"EHC van Dijk","year":"2018","unstructured":"van Dijk\u00a0EHC et\u00a0al (2018) Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial. Ophthalmology 125(10):1547\u20131555","journal-title":"Ophthalmology"},{"issue":"9","key":"2221_CR11","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00347-021-01376-7","volume":"118","author":"L Pauleikhoff","year":"2021","unstructured":"Pauleikhoff\u00a0L, Agostini\u00a0H, Lange\u00a0C (2021) Central serous chorioretinopathy. Ophthalmologe 118(9):967\u2013980","journal-title":"Ophthalmologe"},{"issue":"1","key":"2221_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00417-023-06255-2","volume":"262","author":"GM Cozzupoli","year":"2024","unstructured":"Cozzupoli\u00a0GM et\u00a0al (2024) Long-term predictors of anti-VEGF treatment response in patients with neovascularization secondary to CSCR: a\u00a0longitudinal study. Graefes Arch Clin Exp Ophthalmol 262(1):73\u201380","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2221_CR13","doi-asserted-by":"crossref","unstructured":"Zhou X et\u00a0al (2022) Risk factors and characteristics of central serous chorioretinopathy with later development of macular neovascularisation detected on OCT angiography: a\u00a0retrospective multicentre observational study. Bmj Open Ophthalmol 7(1)","DOI":"10.1136\/bmjophth-2022-000976"},{"issue":"7","key":"2221_CR14","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1136\/bjophthalmol-2019-314625","volume":"104","author":"K Romdhane","year":"2020","unstructured":"Romdhane\u00a0K et\u00a0al (2020) Predictors of treatment response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for choroidal neovascularisation secondary to chronic central serous chorioretinopathy. Br J Ophthalmol 104(7):910\u2013916","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"2221_CR15","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s00417-019-04297-z","volume":"257","author":"F Sulzbacher","year":"2019","unstructured":"Sulzbacher\u00a0F et\u00a0al (2019) Clinical evaluation of neovascular and non-neovascular chronic central serous chorioretinopathy (CSC) diagnosed by swept source optical coherence tomography angiography (SS OCTA). Graefes Arch Clin Exp Ophthalmol 257(8):1581\u20131590","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2221_CR16","first-page":"7217906","volume":"p","author":"JH Yeo","year":"2020","unstructured":"Yeo\u00a0JH et\u00a0al (2020) Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy: OCT Angiography Findings and Risk Factors. J\u00a0Ophthalmol p:7217906","journal-title":"J Ophthalmol"},{"key":"2221_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ajo.2021.05.029","volume":"232: p","author":"DS Ng","year":"2021","unstructured":"Ng\u00a0DS et\u00a0al (2021) Optical Coherence Tomography Angiography Compared with Multimodal Imaging for Diagnosing Neovascular Central Serous Chorioretinopathy. Am J Ophthalmol 232: p:70\u201382","journal-title":"Am J Ophthalmol"},{"key":"2221_CR18","doi-asserted-by":"publisher","first-page":"100770","DOI":"10.1016\/j.preteyeres.2019.07.003","volume":"73: p","author":"TJ van Rijssen","year":"2019","unstructured":"van Rijssen\u00a0TJ et\u00a0al (2019) Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Prog Retin Eye Res 73: p:100770","journal-title":"Prog Retin Eye Res"},{"issue":"5","key":"2221_CR19","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide\u00a0RF et\u00a0al (2020) Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology 127(5):616\u2013636","journal-title":"Ophthalmology"},{"key":"2221_CR20","doi-asserted-by":"publisher","first-page":"101113","DOI":"10.1016\/j.preteyeres.2022.101113","volume":"92: p","author":"R Sacconi","year":"2023","unstructured":"Sacconi\u00a0R et\u00a0al (2023) Towards a\u00a0better understanding of non-exudative choroidal and macular neovascularization. Prog Retin Eye Res 92: p:101113","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"2221_CR21","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2018.12.048","volume":"126","author":"S Mrejen","year":"2019","unstructured":"Mrejen\u00a0S et\u00a0al (2019) Long-term Visual Outcomes and Causes of Vision Loss in Chronic Central Serous Chorioretinopathy. Ophthalmology 126(4):576\u2013588","journal-title":"Ophthalmology"},{"key":"2221_CR22","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.2147\/OPTH.S151933","volume":"11: p","author":"NA Dhirani","year":"2017","unstructured":"Dhirani\u00a0NA, Yang\u00a0Y, Somani\u00a0S (2017) Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy. Clin Ophthalmol 11: p:2145\u20132149","journal-title":"Clin Ophthalmol"},{"issue":"Suppl\u00a01","key":"2221_CR23","first-page":"1","volume":"116","author":"Professional Association of German, O., S.\u00a0German Ophthalmological, and V.\u00a0German Retina Society e.","year":"2017","unstructured":"Professional Association of German, O., S.\u00a0German Ophthalmological, and V.\u00a0German Retina Society e. (2017) Statement of the BVA, the DOG, and the RG on treatment of choroidal neovascularization in diseases other than neovascular age-related macular degeneration. Ophthalmologe 116(Suppl\u00a01):1\u20139","journal-title":"Ophthalmologe"},{"issue":"5","key":"2221_CR24","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ajo.2015.02.002","volume":"159","author":"R Hage","year":"2015","unstructured":"Hage\u00a0R et\u00a0al (2015) Flat irregular retinal pigment epithelium detachments in chronic central serous chorioretinopathy and choroidal neovascularization. Am J Ophthalmol 159(5):890\u2013903","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"2221_CR25","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1136\/bjophthalmol-2019-315318","volume":"105","author":"T Liu","year":"2021","unstructured":"Liu\u00a0T et\u00a0al (2021) Optical coherence tomography angiography of flat irregular pigment epithelial detachments in central serous chorioretinopathy. Br J Ophthalmol 105(2):233\u2013238","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"2221_CR26","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1097\/IAE.0000000000001748","volume":"38","author":"R Pokroy","year":"2018","unstructured":"Pokroy\u00a0R et\u00a0al (2018) Prognostic Value of Subretinal Hyperreflective Material in Neovascular Age-Related Macular Degeneration Treated with Bevacizumab. Retina 38(8):1485\u20131491","journal-title":"Retina"},{"issue":"1","key":"2221_CR27","doi-asserted-by":"publisher","first-page":"126","DOI":"10.4103\/ijo.IJO_265_19","volume":"68","author":"NK Sahoo","year":"2020","unstructured":"Sahoo\u00a0NK et\u00a0al (2020) Subretinal hyperreflective material in central serous chorioretinopathy. Indian J Ophthalmol 68(1):126\u2013129","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"2221_CR28","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1167\/iovs.16-20967","volume":"58","author":"M Hata","year":"2017","unstructured":"Hata\u00a0M et\u00a0al (2017) Intraocular Vascular Endothelial Growth Factor Levels in Pachychoroid Neovasculopathy and Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci 58(1):292\u2013298","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"2221_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/ICU.0000000000000469","volume":"29","author":"EW Schneider","year":"2018","unstructured":"Schneider\u00a0EW, Fowler\u00a0SC (2018) Optical coherence tomography angiography in the management of age-related macular degeneration. Curr Opin Ophthalmol 29(3):217\u2013225","journal-title":"Curr Opin Ophthalmol"},{"issue":"10","key":"2221_CR30","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1038\/s41433-020-01345-5","volume":"35","author":"J Guo","year":"2021","unstructured":"Guo\u00a0J et\u00a0al (2021) OCTA evaluation of treatment-naive flat irregular PED (FIPED)-associated CNV in chronic central serous chorioretinopathy before and after half-dose PDT. Eye (Lond) 35(10):2871\u20132878","journal-title":"Eye (Lond)"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-025-02221-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-025-02221-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-025-02221-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T11:55:04Z","timestamp":1749729304000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-025-02221-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2221"],"URL":"https:\/\/doi.org\/10.1007\/s00347-025-02221-x","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"type":"print","value":"2731-720X"},{"type":"electronic","value":"2731-7218"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"1 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"N.\u00a0Kleefeldt, S.\u00a0Kuehnel, L.\u00a0Reiser, W.\u00a0Goebel, J.\u00a0Hillenkamp und A.\u00a0William geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Alle beschriebenen Untersuchungen am Menschen oder an menschlichem Gewebe wurden mit Zustimmung der zust\u00e4ndigen Ethikkommission, im Einklang mit nationalem Recht sowie gem\u00e4\u00df der Deklaration von Helsinki von 1975 (in der aktuellen, \u00fcberarbeiteten Fassung) durchgef\u00fchrt. Von allen beteiligten Patient\/-innen liegt eine Einverst\u00e4ndniserkl\u00e4rung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}